The analysis was presented at ESC Congress 2020 and published in JACC: CardioOncology.
The designation covers patients with and without diabetes.
The AI algorithm was trained using photographs of more than 5,000 patients.
The authors tracked more than 108,000 patients who suffered their first heart attack between 2009 and 2013.
The wearable devices were designed to detect such conditions as cardiovascular disease, coronary artery disease and ischemic heart disease.
The ThyrAMI-2 trial tracked 95 patients for 52 weeks of treatment.
The peptide-derived drug, M3mP6 HLPN, prevents blood clots without increasing the risk of bleeding.
Innovate Healthcare thanks our partners for supporting our newsletters.Sponsorship has no influence on editorial content.Interested in reaching our audiences, contact our team*|LIST:ADDRESSLINE|*You received this email because you signed up for newsletters from Innovate Healthcare.Change your preferences or unsubscribe hereContact Us | Unsubscribe from all | Privacy Policy© Innovate Healthcare, a TriMed Media brand
